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Abstract A potent inhibitor of a dual-speci¢city protein phos-
phatase, VHR (vaccinia H1 related), was isolated during a
screening of microbial metabolites. This inhibitor was identi¢ed
as 4-isoavenaciolide (4-iA), and was determined to irreversibly
inhibit VHR phosphatase activity with a 50% inhibitory concen-
tration of 1.2 WM. Detailed tandem mass spectrometry analyses
of proteolysed fragments revealed that two molecules of 4-iA
bound a molecule of VHR at the two di¡erent fragments: one
containing the catalytic domain and the other containing the K6
helix positioned surface domain. As 4-iA possesses a reactive
exo-methylene moiety, it is possible that 4-iA inhibits VHR
through the direct binding to the cysteine residue in the catalytic
site (Cys124). Furthermore, 4-iA inhibited dual-speci¢city pro-
tein phosphatases and tyrosine phosphatases, but did not inhibit
serine/threonine phosphatases. These results suggest that 4-iA is
a cysteine-targeting inhibitor of protein phosphatases with a
common HCX5RS/T motif in the catalytic site. 2 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Protein phosphorylation is a fundamental regulation mech-
anism of intracellular signal transduction and is involved in
important cellular events such as growth and di¡erentiation.
Phosphorylation level of proteins is strictly controlled by var-
ious protein kinases and protein phosphatases [1,2]. Dual-
speci¢city phosphatases (DSPases) are a subfamily of protein
tyrosine phosphatases (PTPases) and hydrolyze not only
phosphotyrosine but also phosphoserine/threonine. VHR
(vaccinia H1 related) is a human DSPase [3] and is thought
to be a negative regulator of the mitogen-activated protein
kinases extracellular signal-regulated kinase (ERK) 1 and
ERK2, which are involved in growth factor signaling [4].
The structure of VHR was determined by X-ray crystallogra-
phy and shown to consist of six K-helices and ¢ve L-strands
[5,6]. PTPases and DSPases share a common consensus amino
acid sequence, HCX5RS/T, in the catalytic domain that is
di¡erent from the corresponding domain of protein serine/
threonine phosphatases [1,7]. In the case of VHR, the cysteine
residue (Cys124) in the active site is located between L5 strand
and K4 helix and it is known that chemical modi¢cation of
this cysteine residue abolishes the DSPase activity [8].
Speci¢c phosphatase inhibitors are proving to be useful
tools for revealing phosphatase-mediated signal transduction
cascades. For example, the potent protein phosphatase 1
(PP1) and protein phosphatase 2A (PP2A) inhibitors, okadaic
acid, phoslactomycin and tautomycin, have been used to in-
vestigate the physiological role of serine/threonine phosphor-
ylation during signal transduction [9^11]. However, to date
only a few DSPase inhibitors, such as sodium arsenate, phe-
nylarsine oxide, and RK-682, have been reported [12,13]. Re-
cently, we described the development of a potent inhibitor of
VHR based on the structure activity relationship between
VHR and RK-682 [14]. However, more selective and potent
DSPase inhibitors are still required to provide a full range of
compounds for inhibitory studies.
During the screening for speci¢c VHR inhibitors from mi-
crobial metabolites, 4-isoavenaciolide (4-iA) was identi¢ed as
an inhibitor of VHR. Turner et al. ¢rst isolated avenaciolide
as an antifungal antibiotic and later they isolated 4-iA as a
stereoisomer of avenaciolide [15,16]. There were several pa-
pers on the biological activity of avenaciolide [17^19]. Since
avenaciolide possesses a reactive exo-methylene group moiety,
it was thought that an adduct with a target protein is formed
by Michael addition and that this leads to inhibition of glu-
tamate transport [20]. However, there is no report on the in-
hibition of phosphatases, moreover, no direct evidence of ad-
ducts formation between the compound and its target protein.
In this paper, we investigated the inhibitory mechanism of
4-iA against VHR and found that the compound covalently
binds to Cys124 at the active site of VHR. Therefore we have
provided structural information to account for the inhibitory
action of 4-iA.
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2. Materials and methods
2.1. Screening microbial extracts for inhibition of VHR
Microbial extracts (5 Wl) dissolved in 50% methanol were added to
50 Wl of the reaction mixture (50 mM sodium succinate (pH 6.0), 1.0
mM EDTA, 150 mM NaCl, 0.04 WM VHR, 0.05% Tween 20). The
phosphatase reaction was started by addition of 50 Wl of 20 mM
p-nitrophenyl phosphate (pNPP). After incubation for 30 min at
37‡C, absorbance at 405 nm was measured by a multiplate reader
(Wallac ARVO, Amersham Pharmacia Biotech).
2.2. Isolation and identi¢cation of the VHR inhibitor
In the course of screening for VHR inhibition, a fungus strain
BAUA-3130 was found to produce an active compound in the culture
broth. Based on morphological characterization, the strain BAUA-
3130 was assigned to the genus Neosartorya [21]. The active com-
pound was extracted with acetone from mycelia and was puri¢ed by
ethyl acetate extraction, and a successive column chromatography on
silica gel and preparative high-performance liquid chromatography
(HPLC).
The molecular formula of the compound was determined by high-
resolution mass spectrometry to be C15H22O4 (molecular weight 266).
This compound was subsequently identi¢ed as 4-iA [16,22] using ex-
tensive analyses with various nuclear magnetic resonance experiments.
2.3. Measurement of various phosphatase activities
Inhibitory activity of 4-iA against various kinds of protein phos-
phatases was measured. Assay conditions of phosphatase activities
(VHR [13], Cdc25B [23], laforin [24], PTP1B [25], CD45 [26], PP1
and 2A [10]) were performed as previously described.
Time-dependent VHR inhibition by 4-iA was determined by incu-
bating VHR (0.75 WM) with 4-iA at concentrations of 0, 1.0, 1.5 and
3.5 WM for 0^240 min followed by measurement of VHR activity. To
examine the reversibility of 4-iA-dependent VHR inhibition, VHR
(0.9 WM) was incubated with 1.9 WM 4-iA at 30‡C for 180 min fol-
lowed by dialysis against 1000-fold of reaction bu¡er. The residual
activity of VHR after dialysis was compared with a control sample
that had not been dialyzed and a sample that had not been incubated
with 4-iA.
2.4. Binding site determination by liquid chromatography^mass
spectrometry (LC^MS) and LC^tandem MS (MS/MS)
A complex of 4-iA and VHR protein was prepared by incubation of
3.75 WM VHR with 6.0 WM 4-iA in reaction bu¡er lacking NaCl for
180 min at 30‡C. Under this condition, approximately 40% of the
VHR activity was inhibited.
The molecular weight of the VHR protein incubated with and
without 4-iA was determined by LC^MS. The protein was desalted
and puri¢ed by reversed phase HPLC (Capcell Pak Phenyl column,
1.5U35 mm; Shiseido, Tokyo, Japan) with a diode-array detector at a
£ow rate of 30 Wl/min. VHR was eluted by a linear gradient of two
solvent systems, A (H2O/acetonitrile/tri£uoroacetic acid at 100:0:0.09)
and B (H2O/acetonitrile/tri£uoroacetic acid at 20:80:0.075). The mo-
lecular weight of the eluted VHR was analyzed using a Finnigan LCQ
ion trap mass spectrometer with an ESI probe.
The proteins were digested with Achromobacter protease I (E/S=
1/100 (w/w)) at 37‡C for 4 h. The generated peptides were separated
on a Mightysil C18 column (1U50 mm; Kanto Chemical, Tokyo,
Japan) by a linear gradient of 2^60% solvent A to solvent B in 30
min and analyzed by LC^MS and LC^MS/MS. MS/MS sequencing
was performed by selection and fragmentation of the precursor ion
with mass di¡erences corresponding to addition of 4-iA.
3. Results
3.1. Isolation and identi¢cation of 4-iA
Microbial metabolites were screened for their ability to in-
hibit VHR activity. The screening used an in vitro enzyme
assay with highly puri¢ed VHR as a target enzyme and
pNPP as a substrate. Culture broths of approximately 650
fungi were screened and an extract of a strain, Neosartorya
sp. BAUA-3130, showed strong inhibitory activity against
VHR. The inhibitor was isolated and identi¢ed as 4-iA (di-
hydro-3-methylene-4-octyl-furo[3,4-b]furan-2,6(3H,4H)-dione
(3aR,4S,6aR), Fig. 1).
3.2. 4-iA is an irreversible inhibitor of VHR
In order to determine the inhibitory mechanism of 4-iA
against VHR, we ¢rst characterized the inhibitory activity
under several di¡erent conditions. The compound inhibited
VHR activity in a time-dependent manner (Fig. 2A). Com-
plete inhibition by 3.5 WM 4-iA was reached at 180 min of
incubation. Subsequently, we tested whether such inhibition
was reversible or not. After incubation of VHR with 4-iA, the
reaction mixture was diluted and dialyzed against phosphate
bu¡er. It would be predicted that if 4-iA is a reversible inhib-
itor, VHR activity should be recovered following dialysis.
However, we found that the VHR activity of the dialysate
was the same as that of an undialyzed sample, indicating
that irreversible inhibition (Fig. 2B). Furthermore, this inhi-
bition by 4-iA was completely abolished in the presence of the
reducing reagent, such as L-mercaptoethanol (data not
shown). These results strongly suggest that the inhibitory ac-
tion of 4-iA is due to the covalent bond formation between
the inhibitor and the target protein, VHR.
3.3. Binding site assignments
Our initial analyses suggested that 4-iA could be covalently
bound to VHR and that this may provide the mechanism of
inhibition. Therefore to verify these observations and to gain
more precise information as to the nature of the covalent
linkage, we measured the molecular weight shift of VHR be-
Fig. 1. Structure of 4-iA.
Fig. 2. Inhibition properties of 4-iA on VHR. A: Time-dependent
inhibition by 4-iA. VHR (0.75 WM) was incubated with various con-
centrations of 4-iA (0, closed squares; 1.0 WM, closed circles; 1.5
WM, open squares; 3.5 WM, open circles) for 0^240 min and the re-
sidual activities measured at the time points indicated. B: Irrevers-
ible inhibition of VHR by 4-iA. VHR (0.9 WM) was incubated for
180 min with 1.9 WM 4-iA followed by dialysis against drug-free
bu¡er. Then, residual activities before (1) and after (2) dialysis are
measured (meanS standard deviation obtained from three indepen-
dent experiments). VHR activity without the drug treatment repre-
sents the 100% value.
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fore and after 4-iA treatment using LC^MS. The molecular
weight of VHR was determined to be 20 345 (Fig. 3, peak a*)
and this is in agreement with that predicted from its amino
acid sequence. However, a range of molecular weights for
4-iA-treated VHR was obtained (Fig. 3). These were a:
20 345 (VHR), b: 20 610 (VHR+4-iA), c: 20 628 (VHR+water
adduct-4iA), d: 20 877 (VHR+2U4-iA), e: 20 895 (VHR+
4-iA+water adduct-4iA) and f: 20 913 (VHR, 2Uwater ad-
duct-4iA). These results suggested that one or two molecules
of 4-iA (molecular weight 266) or water adduct-4iA (molec-
ular weight 284) are able to covalently bind to a VHR mol-
ecule under conditions in which VHR activity is inhibited.
Following the demonstration that two molecules of 4-iA are
able to covalently bind to VHR, we decided to precisely de-
termine the 4-iA binding sites. VHR was incubated in the
presence or absence of 4-iA, and digested with Achromobacter
protease I. Then, the resulting peptides were analyzed by LC^
MS. The amino acid sequences of the digested peptides were
deduced based on the molecular masses. We detected doublet
extra masses with the 4-iA-treated protein di¡erence between
calculated and observed masses. These masses corresponded
to peptides #9 and #10 with 4-iA (v 266.5, 265.6) and water-
adducted 4-iA (v 284.9, 284.8), respectively. Using more de-
tailed analyses of these peptides by MS/MS, fragment ions
were detected and assigned. In peptide #9, b11, b16 and y26
obtained fragments (m/z 745.2 (b2þ11 ), 1039.7 (b
2þ
16 ), and 1609.0
(y2þ25 )) increased about 266 more than the predicted fragments
(m/z 611.7 (b2þ11 ), 907.0 (b
2þ
16 ), and 1476.8 (y
2þ
25 )) which account
for the peptide containing 4-iA (molecular weight 266). Other
Fig. 3. 4-iA covalently binds to VHR. Molecular weight changes of
VHR by treatment with 4-iA as determined by LC^MS. A: Mass
spectrum of control and 4-iA-treated VHR. a*: control, and a^f:
4-iA-treated VHR ion peaks. Molecular weights were determined as
20 345 (a* and a), 20 610 (b), 20 628 (c), 20 877 (d), 20 895 (e), and
20 913 (f).
Fig. 4. 4-iA binding sites assignment. 4-iA binding sites were deter-
mined by LC^MS/MS. A: MS/MS spectrum of triply charged pep-
tide #9 (m/z, 1094.0). Cleaved peptide fragments (singly charged b7
and doubly charged b11, b16, y20 and y25) were identi¢ed. Pre-
dicted peptide fragments are given parentheses. B: MS/MS spectrum
of triply charged peptide #10 (m/z, 1148.0). Cleaved peptide frag-
ments (singly charged y4, y8, and y15 and doubly charged b16, b22,
and b27) were identi¢ed.
Table 1
Theoretical peptides and mass (Da) after digestion by Achromobacter protease I
No. Predicted peptide sequence Calculated (Da) Observed (Da) v (Da)
1: P 115.1 ^ ^
2: LK 259.4 ^ ^
3: EGK 332.4 ^ ^
4: LQK 387.5 ^ ^
5: MDVK 491.6 491.0 0.6
6: DSGITYLGIK 1066.2 1066.5 0.3
7: LGITHVLNAAEGRSMHVNTNANFYK 2905.3 2906.2 0.9
8: ANDTQEFNLSAYFERAADFIDQALAQK 3077.3 3076.8 0.5
9: NGRVLVHCREGYSRSPTLVIAYLMMRQK 3278.9 3545.4 (3563.8) 266.5 (284.9)
10: SALSIVRQNREIGPNDGFLAQLCQLNDRLAK 3440.9 3706.5 (3726.7) 265.6 (284.8)
11: SGSFELSVQDLNDLLSDGSGCYSLPSQPCNEVTPRIYVGNASVAQDIPK 5172.7 5171.7 1.0
v (Da) is the di¡erence between calculated and observed masses in Da. 4-iAv and water-adducted 4-iAv were observed in both peptides 9
and 10.
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fragments (b1þ7 and y
2þ
20 ) did not change after treatment with
4-iA (Fig. 4A). Likewise in peptide #10, b27 and y15 obtained
fragments (m/z 1611.8 (b2þ27 ) and 1956.8 (y
1þ
15 )) increased the
number more than the predicated fragments (m/z 1478.2 (b2þ27 ),
and 1691.0 (y1þ15 )). Other fragments (b16, b22, y8 and y4) did
not change after treatment with 4-iA (Fig. 4B). These results
demonstrated that the binding sites of 4-iA to VHR were
Cys124 on peptide #9 and Cys171 on peptide #10, respec-
tively (Fig. 4A,B). Interestingly Cys124 is located in the cata-
lytic site of VHR and therefore covalent binding of 4-iA at
this site would indeed be predicted to inhibit phosphatase
activity.
3.4. 4-iA inhibits DSPases and PTPases, but not serine/
threonine phosphatases
The inhibitory activity of 4-iA is rather potent against VHR
with a 50% inhibitory concentration (IC50) value of 1.2 WM.
To determine whether the inhibitory activity of 4-iA is speci¢c
for VHR, we tested its inhibitory activity against other protein
phosphatases (Table 2). RK-682 and arsenate are known
PTPase inhibitors and inhibited DSPases and PTPases, but
had no inhibitory activity against PP1 or PP2A. Tautomycin,
known to be a potent PP1/PP2A inhibitor, inhibited PPases,
but not DSPases and PTPases. 4-iA potently inhibited
DSPases (IC50 1.2^9.4 WM) and PTP1B (IC50 10.7 WM), and
weakly inhibited CD45 (IC50 245 WM). However, PPases (PP1
and PP2A) were not inhibited by 4-iA even at a concentration
of 250 WM. These results suggested that 4-iA is a potent
DSPase and PTPase inhibitor.
4. Discussion
Protein phosphatase inhibitors are useful tools to reveal
signal transduction pathways of immune response as well as
to cure immunological diseases [27,28]. In this report, we iden-
ti¢ed 4-iA as a potent VHR inhibitor and investigated the
e¡ect of 4-iA on VHR, a well-characterized member of
DSPases. Avenaciolide was originally reported as an antifun-
gal compound (minimal inhibitory concentration 10 Wg/
ml = 40 WM) [15] and its target was predicted to be a compo-
nent of the mitochondria (IC50 12.5 Wg/ml = 47 WM) [17^20].
Subsequently 4-iA was isolated as a stereoisomer of avenacio-
lide and synthesized [16,22], however, its biological activity
and mechanism of action were not reported. In this work,
we have isolated 4-iA from culture broth of Neosartorya sp.,
which is teleomorph of some species of Aspergillus, then we
have characterized the inhibitory mode of action of 4-iA on
VHR. Inhibition of VHR activity by 4-iA seemed to be irre-
versible (Fig. 2B). Analyses of LC^MS pro¢les suggested that
two molecules of 4-iA covalently bound to a VHR molecule
(Fig. 3). To determine the binding sites of 4-iA on the VHR,
peptides were prepared by protease digestion (Table 1). Anal-
yses of LC^MS/MS suggested the two 4-iA binding sites were
located on Cys124 in the catalytic domain (residues 123^131)
and Cys171 in the K6 helix (residues 163^179) on the surface
of VHR (Fig. 4). The data suggest that 4-iA covalently binds
to the SH group of cysteine residues by 1,4-addition (Michael
addition) in the same manner as avenaciolide [20]. As shown
in Fig. 5, there are four cysteine residues in a VHR molecule.
We anticipated that 4-iA might bind to any cysteine residue
without selectivity, because the exo-methylene moiety should
be highly reactive. However, 4-iA bound to Cys124 in the
active site and Cys171 on the surface of VHR (K6), but not
to Cys22 and Cys30. These observations suggest that a hydro-
phobic cleft near a cysteine residue is required for the adduct
formation between 4-iA and the target protein. This assump-
tion is consistent with the previous report, moreover, 4-iA
derivatives with a shorter alkyl chain at the 4-position have
weaker inhibitory activity (data not shown).
4-iA potently inhibited DSPases and PTP1B with a IC50
range of 1^10 WM. However, the inhibitory activity of 4-iA
is rather weak to CD45 (IC50 245 WM) and LAR [29] (IC20 30
WM, data not shown). Apparently, 4-iA may potently inhibit
non-receptor type phosphatases (VHR, Cdc25 etc.) more than
receptor type phosphatases (CD45 and LAR), but there is
more clear selectivity of 4-iA in respect of tyrosine phospha-
tases (DSPase, PTPase) vs. serine/threonine phosphatases. The
catalytic center of DSPases and PTPases has a consensus se-
quence, HCX5RS/T [1,7], which is a target site of 4-iA. On the
Fig. 5. Proposed binding image of 4-iA on VHR.
Table 2
IC50 values (WM) for various phosphatases
Compound DSPases PTPases PPases
VHR Cdc25B Laforin PTP1B CD45 PP1 PP2A
4-iA 1.2S 0.1 9.4S 1.0 1.8S 0.4 10.7S 0.8 244.6S 3.3 s 250 s 250
RK-682 11.6S 0.5 10.4S 0.8 40.4S 5.8 39.2S 0.5 13.4S 0.2 s 250 s 250
Arsenate 65.0S 5.5 212.0S 18.5 35.1S 4.5 76.9S 2.5 90.8S 0.9 s 250 s 250
Tautomycin s 200 s 200 s 200 s 200 s 200 0.03S0.0 0.05S 0.1
IC50 values for various phosphatases by 4-iA are shown. The meanS standard deviation from three independent experiments for VHR (0.75
WM) and Cdc25B (0.05 WM), and the meanS standard deviation from two independent experiments for laforin (0.01 WM), PTP1B (0.07 WM),
DC45 (0.02 WM), PP1 (0.05 U) and PP2A (0.005 U) are shown.
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contrary, since the catalytic site of PPases is di¡erent from
that of DSPases, 4-iA did not inhibit PPases even at 250 WM
(Table 2). This is the ¢rst report revealing the covalent bind-
ing of 4-iA to a protein phosphatase, VHR and the amino
acid sequences involved in the adduct formation.
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